STRIDE immunotherapy sets new benchmark for survival in advanced liver cancer
A new exploratory analysis of the HIMALAYA phase III trial involving patients with unresectable hepatocellular carcinoma (uHCC, an advanced liver cancer that could not be treated with surgery or other…